FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|October 15, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Immunotherapy and Viral Therapy for Pancreatic Cancer
Tanios Bekaii-Saab, MD, discusses the future of immunotherapy and viral therapy for the treatment of pancreatic cancer.
Advertisement
Articles in this issue
almost 12 years ago
Unanswered Questions Regarding the Treatment of Pancreatic NETsalmost 12 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsalmost 12 years ago
Sequencing Agents for the Treatment of Pancreatic NETsalmost 12 years ago
Research on Epidemiology of GIST Identifies Risk Factorsalmost 12 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationalmost 12 years ago
Coping With Comorbidities in Hepatocellular Canceralmost 12 years ago
Strategies in Surveillance: Hepatocellular CarcinomaAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
5